1. Home
  2. STRO vs VNDA Comparison

STRO vs VNDA Comparison

Compare STRO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STRO
  • VNDA
  • Stock Information
  • Founded
  • STRO 2003
  • VNDA 2002
  • Country
  • STRO United States
  • VNDA United States
  • Employees
  • STRO N/A
  • VNDA N/A
  • Industry
  • STRO Biotechnology: Biological Products (No Diagnostic Substances)
  • VNDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • STRO Health Care
  • VNDA Health Care
  • Exchange
  • STRO Nasdaq
  • VNDA Nasdaq
  • Market Cap
  • STRO 77.7M
  • VNDA 261.7M
  • IPO Year
  • STRO 2018
  • VNDA 2006
  • Fundamental
  • Price
  • STRO $0.81
  • VNDA $4.91
  • Analyst Decision
  • STRO Hold
  • VNDA Strong Buy
  • Analyst Count
  • STRO 7
  • VNDA 3
  • Target Price
  • STRO $3.97
  • VNDA $15.33
  • AVG Volume (30 Days)
  • STRO 1.4M
  • VNDA 388.0K
  • Earning Date
  • STRO 08-12-2025
  • VNDA 07-30-2025
  • Dividend Yield
  • STRO N/A
  • VNDA N/A
  • EPS Growth
  • STRO N/A
  • VNDA N/A
  • EPS
  • STRO N/A
  • VNDA N/A
  • Revenue
  • STRO $66,434,000.00
  • VNDA $201,351,000.00
  • Revenue This Year
  • STRO N/A
  • VNDA $16.86
  • Revenue Next Year
  • STRO N/A
  • VNDA $39.78
  • P/E Ratio
  • STRO N/A
  • VNDA N/A
  • Revenue Growth
  • STRO N/A
  • VNDA 13.37
  • 52 Week Low
  • STRO $0.52
  • VNDA $3.81
  • 52 Week High
  • STRO $5.17
  • VNDA $6.37
  • Technical
  • Relative Strength Index (RSI)
  • STRO 51.04
  • VNDA 62.83
  • Support Level
  • STRO $0.73
  • VNDA $4.85
  • Resistance Level
  • STRO $0.79
  • VNDA $5.07
  • Average True Range (ATR)
  • STRO 0.06
  • VNDA 0.16
  • MACD
  • STRO 0.00
  • VNDA 0.02
  • Stochastic Oscillator
  • STRO 69.90
  • VNDA 76.81

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: